Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918420 | 0.83 | KCNA5 (0.33) | TRPV1SCN5ASCN9A | |
| SCHEMBL5478057 | 0.82 | TRPV1 (0.45) | TRPV1SCN5ASCN9A | |
| SCHEMBL5918385 | 0.82 | NOTUM (0.33) | TRPV1 | |
| SCHEMBL5918391 | 0.81 | TRPV1 (0.47) | TRPV1SCN5ASCN9A | |
| SCHEMBL5918310 | 0.81 | CNR2 (0.43) | TRPV1 | |
| SCHEMBL5471296 | 0.79 | TRPV1 (0.47) | TRPV1SCN5ASCN9A | |
| SCHEMBL14430630 | 0.79 | TRPV1 (0.50) | TRPV1SCN5ASCN9A | |
| SCHEMBL4718329 | 0.77 | CYP2A6 (0.51) | TRPV1 | |
| SCHEMBL5918417 | 0.77 | GABRG2 (0.36) | — | |
| SCHEMBL6430247 | 0.77 | CYP2A6 (0.49) | TRPV1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213332-A1 | Prodrugs Of Substituted Amino Heterobicycles Which Modulate The Function Of The Vanilloid-1 Receptor (Vr1) | MERCK SHARP & DOHME LTD. (GB) | 2007-09-13 | — | — | US | disclosed |
| CN-1918159-A | Substituted aminoheterobicyclic prodrugs that modulate vanilloid-1 receptor (VR1) function | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | CN | disclosed |
| US-20060154930-A1 | Substituted amino heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-07-13 | — | — | US | disclosed |
| EP-1597261-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004074290-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154930-A1 | Substituted amino heterocycles as vr-1 antagonists for treating pain | OPRL1, OPRM1, OPRK1 | TRPV1 58/4885SCN5A 466/4885SCN9A 412/4885 |
| US-20070213332-A1 | Prodrugs Of Substituted Amino Heterobicycles Which Modulate The Function Of The Vanilloid-1 Receptor (Vr1) | TRPV1, TRPV2, TRPV6 | TRPV1 1/4885SCN5A 203/4885SCN9A 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.